Low-dose overlap initiation with split tablets of buprenorphine in intubated intensive care unit patients with opioid use disorder.

IF 4 2区 社会学 Q1 SUBSTANCE ABUSE
Laura Szczesniak, Sarah Britton, Theresa Baxter Rn, Ross Sullivan
{"title":"Low-dose overlap initiation with split tablets of buprenorphine in intubated intensive care unit patients with opioid use disorder.","authors":"Laura Szczesniak, Sarah Britton, Theresa Baxter Rn, Ross Sullivan","doi":"10.1186/s12954-024-01028-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>As the opioid public health crisis evolves to include fentanyl and other potent synthetic opioids, more patients are admitted to the hospital with serious complications of drug use and frequently require higher levels of care, including intensive care unit (ICU) admission, for acute and chronic conditions related to opioid use disorder (OUD). This patient population poses a unique challenge when managing sedation and ensuring adequate ventilation while intubated given their high opioid requirements. Starting a patient on medications such as buprenorphine may be difficult for inpatient providers unfamiliar with its use, which may lead to undertreatment of patients with OUD, prolonged mechanical ventilation and length of stay.</p><p><strong>Methods: </strong>We developed a 7-day buprenorphine low dose overlap initiation (LDOI) schedule for patients with OUD admitted to the ICU (Table 1). Buprenorphine tablets were split by pharmacists and placed into pre-made blister packs as a kit to be loaded into the automated medication dispensing machine for nursing to administer daily. An internal quality review validated the appropriate dosing of split-dose tablets. To simplify order entry and increase prescriber comfort with this new protocol, we generated an order set within our electronic health record software with prebuilt buprenorphine titration orders. This protocol was implemented alongside patient and healthcare team education and counseling on the LDOI process, with follow-up offered to all patients upon discharge.</p><p><strong>Results: </strong>Here we report a series of 6 ICU patients started on buprenorphine using the LDOI schedule with split buprenorphine tablets. None of the 6 patients experienced precipitated withdrawal upon buprenorphine initiation using the LDOI schedule, and 5/6 patients were successfully extubated during the buprenorphine initiation. Four of six patients had a decrease in daily morphine milligram equivalents, with 3 patients transitioning to buprenorphine alone.</p><p><strong>Conclusion: </strong>Initiating buprenorphine via LDOI was found to be successful in the development of a protocol for critically ill patients with OUD. We examined LDOI of buprenorphine in intubated ICU patients and found no events of acute precipitated withdrawal. This protocol can be used as a guide for other institutions seeking to start critically ill patients on medication treatment for OUD during ICU admission.</p>","PeriodicalId":12922,"journal":{"name":"Harm Reduction Journal","volume":"21 1","pages":"114"},"PeriodicalIF":4.0000,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11157744/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Harm Reduction Journal","FirstCategoryId":"90","ListUrlMain":"https://doi.org/10.1186/s12954-024-01028-4","RegionNum":2,"RegionCategory":"社会学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
引用次数: 0

Abstract

Background: As the opioid public health crisis evolves to include fentanyl and other potent synthetic opioids, more patients are admitted to the hospital with serious complications of drug use and frequently require higher levels of care, including intensive care unit (ICU) admission, for acute and chronic conditions related to opioid use disorder (OUD). This patient population poses a unique challenge when managing sedation and ensuring adequate ventilation while intubated given their high opioid requirements. Starting a patient on medications such as buprenorphine may be difficult for inpatient providers unfamiliar with its use, which may lead to undertreatment of patients with OUD, prolonged mechanical ventilation and length of stay.

Methods: We developed a 7-day buprenorphine low dose overlap initiation (LDOI) schedule for patients with OUD admitted to the ICU (Table 1). Buprenorphine tablets were split by pharmacists and placed into pre-made blister packs as a kit to be loaded into the automated medication dispensing machine for nursing to administer daily. An internal quality review validated the appropriate dosing of split-dose tablets. To simplify order entry and increase prescriber comfort with this new protocol, we generated an order set within our electronic health record software with prebuilt buprenorphine titration orders. This protocol was implemented alongside patient and healthcare team education and counseling on the LDOI process, with follow-up offered to all patients upon discharge.

Results: Here we report a series of 6 ICU patients started on buprenorphine using the LDOI schedule with split buprenorphine tablets. None of the 6 patients experienced precipitated withdrawal upon buprenorphine initiation using the LDOI schedule, and 5/6 patients were successfully extubated during the buprenorphine initiation. Four of six patients had a decrease in daily morphine milligram equivalents, with 3 patients transitioning to buprenorphine alone.

Conclusion: Initiating buprenorphine via LDOI was found to be successful in the development of a protocol for critically ill patients with OUD. We examined LDOI of buprenorphine in intubated ICU patients and found no events of acute precipitated withdrawal. This protocol can be used as a guide for other institutions seeking to start critically ill patients on medication treatment for OUD during ICU admission.

对患有阿片类药物使用障碍的插管重症监护病房患者使用丁丙诺啡分片进行低剂量重叠起始治疗。
背景:随着阿片类药物公共卫生危机发展到包括芬太尼和其他强效合成阿片类药物,越来越多的患者因吸毒引起严重并发症而入院,并经常需要更高级别的护理,包括入住重症监护室(ICU),以治疗与阿片类药物使用障碍(OUD)相关的急性和慢性疾病。由于这类患者对阿片类药物的需求量很大,因此在插管时管理镇静和确保充分通气是一项独特的挑战。对于不熟悉丁丙诺啡等药物使用方法的住院医护人员来说,让患者开始使用这些药物可能会很困难,这可能会导致对 OUD 患者的治疗不足、机械通气时间延长和住院时间延长:我们为入住重症监护室的 OUD 患者制定了为期 7 天的丁丙诺啡低剂量重叠起始(LDOI)计划(表 1)。药剂师将丁丙诺啡药片拆分,装入预制的泡罩包装中,作为药盒装入自动配药机,供护理人员每日用药。内部质量审查验证了分剂量药片的适当剂量。为了简化医嘱输入并提高处方医生对这一新方案的适应性,我们在电子病历软件中生成了一套预设丁丙诺啡滴定医嘱。在实施该方案的同时,我们还对患者和医疗团队进行了有关 LDOI 流程的教育和咨询,并在所有患者出院时对其进行了随访:在此,我们报告了 6 名重症监护室患者开始使用丁丙诺啡的情况。使用 LDOI 计划开始服用丁丙诺啡时,6 名患者中没有一人出现骤然戒断,5/6 名患者在开始服用丁丙诺啡期间成功拔管。六名患者中有四名患者的每日吗啡毫克当量有所减少,其中三名患者过渡到仅使用丁丙诺啡:结论:通过 LDOI 启动丁丙诺啡在为 OUD 重症患者制定方案时取得了成功。我们对 ICU 插管患者的丁丙诺啡 LDOI 进行了检查,没有发现急性骤停事件。该方案可作为指南,供其他机构在重症监护病房收治重症患者时开始对其进行药物治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Harm Reduction Journal
Harm Reduction Journal Medicine-Public Health, Environmental and Occupational Health
CiteScore
5.90
自引率
9.10%
发文量
126
审稿时长
26 weeks
期刊介绍: Harm Reduction Journal is an Open Access, peer-reviewed, online journal whose focus is on the prevalent patterns of psychoactive drug use, the public policies meant to control them, and the search for effective methods of reducing the adverse medical, public health, and social consequences associated with both drugs and drug policies. We define "harm reduction" as "policies and programs which aim to reduce the health, social, and economic costs of legal and illegal psychoactive drug use without necessarily reducing drug consumption". We are especially interested in studies of the evolving patterns of drug use around the world, their implications for the spread of HIV/AIDS and other blood-borne pathogens.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信